medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2019, Number 1

<< Back

Rev Med UAS 2019; 9 (1)

Diagnostic performance of serum procalcitonin in the diagnosis of sepsis in patients with chronic kidney disease

Dehesa LE, Osuna LÁI

Language: Spanish
References: 26
Page: 38-47
PDF size: 116.42 Kb.


ABSTRACT

Chronic kidney disease (CKD) is considered a state of acquired immunodeficiency and, therefore, an infectious complication may be more serious than in the general population. Being a pro-inflammatory disorder some acute response biomarkers could be elevated, like C-Reactive Protein (CRP) and procalcitonin (PCT). The PCT, the precursor of calcitonin, is produced in several inflammatory processes and has been associated as a serum marker of sepsis. On patients with CKD, unlike in healthy patients, hematic levels of procalcitonin of 0.25 – 0.61 ng/ml are considered normal thus, this review include the latest reports about the procalcitonin levels in CKD for the diagnosis of infection or sepsis.


REFERENCES

  1. Ketteler M, Block GA, Evenepoel P, FukagawaM, Herzog CA, McCann L. et al. KDIGO 2017Clinical Practice Guideline Update for the Diagnosis,Evaluation, Prevention, and Treatment ofChronic Kidney Disease–Mineral and Bone Disorder(CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.

  2. Espinosa-Cuevas MA. Enfermedad renal. GacMed Mex. 2016;152:1.

  3. Webster AC, Nagler EV, Morton RL, Masson P.Chronic Kidney Disease. The Lancet.2017;389(10075):1238-52.

  4. Naqvi SB, Collins AJ. Infectious complications inchronic kidney disease. Adv Chronic Kidney Dis.2006;13(3):199-204.

  5. Méndez-Durán A, Méndez-Bueno JF, Tapia-YáńezT, Montes AM, Aguilar-Sánchez L. Epidemiologíade la insuficiencia renal crónica en México.Dial Traspl. 2010;31(1):7-11.

  6. Sarnak MJ, Jaber BL. Mortality caused by sepsisin patients with end-stage renal disease comparedwith the general population. Kidney Int.2000;58(4):1758-64.

  7. Coresh J, Selvin E, Stevens LA, Manzi J, KusekJW, Eggers P, et al. Prevalence of chronic kidneydisease in the United States. JAMA.2007;298(17):2038-47.

  8. Quiroga B, Villaverde M, Vega A, Abad S, RequeJ, López-Gómez JM. Procalcitonin as an earlypredictor of acute infection in hemodialysis patients.Nefrologia. 2014;34(3):341-6.

  9. Contou D, d'Ythurbide G, Messika J, Ridel C,Parrot A, Djibré M, et al. Description and predictivefactors of infection in patients with chronickidney disease admitted to the critical care unit.J Infect. 2014;68(2):105-15.

  10. Dahaba AA, Rehak PH, List WF. Procalcitoninand C-reactive protein plasma concentrations innonseptic uremic patients undergoing hemodialysis.Int Care Med. 2003;29(4):579-83.

  11. Lu X-L, Xiao Z-H, Yang M-Y, Zhu Y-M. Diagnosticvalue of serum procalcitonin in patients withchronic renal insufficiency: a systematic reviewand meta-analysis. Nephrol Dial Transplant.2012;28(1):122-9.

  12. Dumea R, Siriopol D, Hogas S, Mititiuc I, CovicA. Procalcitonin: diagnostic value in systemic infectionsin chronic kidney disease or renal transplantpatients. Int Urol Nephrol. 2014;46(2):461-8.

  13. Grace E, Turner RM. Use of procalcitonin in patientswith various degrees of chronic kidney diseaseincluding renal replacement therapy. ClinInfect Dis. 2014;59(12):1761-7.

  14. Park JH, Kim DH, Jang HR, Kim MJ, Jung SH,Lee JE, et al. Clinical relevance of procalcitoninand C-reactive protein as infection markers in renalimpairment: a cross-sectional study. CritCare. 2014;18(6):640.

  15. Steinbach G, Bölke E, Grünert A, Orth K, StörckM. Procalcitonin in patients with acute andchronic renal insufficiency. Wien Klin WochenschrSuppl. 2004;116(24):849-53.

  16. Schuetz P, Birkhahn R, Sherwin R, Jones AE,Singer A, Kline JA, et al. Serial Procalcitonin PredictsMortality in Severe Sepsis Patients: ResultsFrom the Multicenter Procalcitonin MOnitoringSEpsis (MOSES) Study. Crit Care Med.2017;45(5):781-9.

  17. Rhodes A, Evans LE, Alhazzani W, Levy MM,Antonelli M, Ferrer R, et al. Surviving sepsiscampaign: international guidelines for managementof sepsis and septic shock: 2016. IntensiveCare Med. 2017;43(3):304-77.

  18. Akbulut HH, Çelik I, Özden M, Doğukan A, BulutV. Plasma procalcitonin levels in chronic haemodialysispatients. Turk J Med Sci.2005;35(4):243-6.

  19. Herget-Rosenthal S, Klein T, Marggraf G, HirschT, Jakob HG, Philipp T, et al. Modulation andsource of procalcitonin in reduced renal functionand renal replacement therapy. Scand J Immunol.

  20. 2005;61(2):180-6.20. Öztürk R, Yilmaz GR, Bulut C, Parpucu H, KinikliS, Duranay M, et al. Assessment of procalcitoninand other inflammatory markers in peritoneal dialysis-related peritonitis. Turk J Med Sci.2010;40(2):199-206.

  21. Mori K-I, Noguchi M, Sumino Y, Sato F, MimataH. Use of Procalcitonin in Patients on ChronicHemodialysis: Procalcitonin Is Not Related withIncreased Serum Calcitonin. ISRN Urol.2012;2012:6.

  22. Trimarchi H, Dicugno M, Muryan A, Lombi F,Iturbe L, Rańa MS, et al. Pro-calcitonin and inflammationin chronic hemodialysis. Medicina (B.Aires). 2013;73(5):411-6.

  23. Jain S, Sinha S, Sharma SK, Samantaray JC,Aggrawal P, Vikram NK, et al. Procalcitonin as aprognostic marker for sepsis: a prospective observationalstudy. BMC Res Notes. 2014;7:458.

  24. Lee WS, Kang DW, Back JH, Kim HL, Chung JH,Shin BC. Cutoff value of serum procalcitonin asa diagnostic biomarker of infection in end-stagerenal disease patients. Korean J Intern Med.2015;30(2):198-204.

  25. Bouadma L, Luyt C-E, Tubach F, Cracco C, AlvarezA, Schwebel C, et al. Use of procalcitoninto reduce patients' exposure to antibiotics in intensivecare units (PRORATA trial): a multicentrerandomised controlled trial. Lancet.2010;375(9713):463-74.

  26. Hohn A, Schroeder S, Gehrt A, Bernhardt K,Bein B, Wegscheider K, et al. Procalcitoninguidedalgorithm to reduce length of antibiotictherapy in patients with severe sepsis and septicshock. BMC Infect. Dis. 2013;13(1):158.




2020     |     www.medigraphic.com